BioSpace News Archive

BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company signed a new consulting agreement with John W. Osborn, Ph.D, Professor,

Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that it has been approved by the Dutch retail conglomerate Ahold Delhaize (“Ahold”) to become a Direct Supplier.

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the continued enhancement of the U.S. and global intellectual property (IP) portfolio governing its lead investigational drug candidate, Seclidemstat. Seclidemstat is now in a Phase 1/2 clinical trial for Ewing sarcoma, a rare pediatric bone cancer, and a Phase 1/2 trial in advanced solid tumors (AST).

Galderma announces significant investments across its aesthetic portfolio including digital enhancements to ASPIRE Galderma Rewards and an expansion of its U.S. salesforce. Additionally, Galderma has launched a collaboration with premium skincare brand ZO® Skin Health

Sarah H. Elsea, PhD, FACMG, professor of molecular and human genetics at Baylor College of Medicine and senior director of biochemical genetics at Baylor Genetics, has been elected to the board of directors of the ACMG Foundation for Genetic and Genomic Medicine.

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (“FDA”) acknowledged receipt of the resubmission of TLANDO New Drug Application (“NDA”), the Company’s oral testosterone product candidate for testosterone replacement therapy (“TRT”) in adult males for conditions associated with a deficiency of endogenous

Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology that enables the functional selection of stem cells, today announced that its Board of Directors has approved, and the company has entered, subject to definitive agreements, into a commercial binding Letter Of Intent (LOI) with Canndoc Ltd, a leading pharma grade medical cannabis pioneer, a wholly owned subsidiary of publicly-traded Intercure Ltd. (TASE: INCR).

DiscGenics, Inc. , a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has completed enrollment in its Phase 1/2 first-in-human U.S. clinical study of IDCT

Nexelis, a portfolio company of Ampersand Capital Partners, and a leading provider of assay development and advanced laboratory testing is pleased to announce the signing of a definitive agreement, subject to conditions precedent, to acquire ImmunXperts.

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced publication of results from a survey of patients with refractory Mycobacterium avium complex (MAC) lung disease on the clinical management of respiratory adverse events (AEs) associated with ARIKAYCE® (amikacin liposome inhalation suspension) treatment